Development and evaluation of nanoparticles based on mPEG-PLA for controlled delivery of vinpocetine: in vitro and in vivo studies

Figures & data

Figure 1. The structure of VIN.

Figure 2. 50 000 × magnified TEM of normally prepared VIN-mPEG–PLA NPs.

Figure 3. Mean particle size of prepared VIN mPEG–PLA NPs.

Table 1. Stability data of VIN mPEG–PLA NPs during 6 months.

Time (month)	25 °C
	Mean particle size (nm)	Zeta potential (mV)	EE (%)
	0	110.6 ± 13.2	−23.4 ± 1.5	76.4 ± 6.3
1	113.3 ± 15.1	−22.5 ± 1.6	75.7 ± 7.5
2	112.1 ± 17.3	−24.1 ± 1.8	75.3 ± 6.9
3	113.4 ± 16.4	−25.2 ± 1.2	74.7 ± 7.6
6	112.7 ± 17.1	−23.9 ± 1.5	75.8 ± 8.1

Figure 4. In vitro release profiles of VIN mPEG–PLA NPs from three batches. Release experiments were carried out in PBS (pH 7.4), at 37 ± 0.5 °C. Each point represents the mean value of three different experiments ± SD. ⋄: VIN injection; △: VIN mPEG–PLA NPs.

Figure 5. Mean plasma concentration (in value)–time profiles of VIN mPEG–PLA NPs and VIN injections. Each point represents the mean value of six SD rats. ⋄: VIN injection; △: VIN mPEG–PLA NPs.

Table 2. Pharmacokinetic parameters of VIN mPEG–PLA NPs and VIN injections (n=6).

Parameter	Groups
	Injection	NPs
	t1/2 (h)	2.32 ± 1.5	5.64 ± 2.4*
Cmax (ng/mL)	2543.5 ± 185.3	3327.7 ± 236.3*
AUC0–t (ng h/mL)	4625.3 ± 543.5	13261.5 ± 621.4*
AUC0–∞ (ng h/mL)	4935.4 ± 567.4	14998.3 ± 742.1*
MRT (h)	1.12 ± 0.6	4.21 ± 1.9*
CL (L/h)	1.42 ± 0.8	0.05 ± 0.02*

*P < 0.05: VIN mPEG–PLA NPs versus VIN injection.